{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:32:11Z","timestamp":1793367131689,"version":"4.5.0"},"reference-count":24,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Ispen"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["NeuroRehabilitation"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>AbobotulinumtoxinA (aboBoNT-A) is approved worldwide in indications related to excessive muscle activity, including focal upper and lower limb spasticity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We evaluated real-world outcomes associated with on-label use of aboBoNT-A for adult focal spasticity in UK routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multicenter, retrospective, 52-week study analyzing data from patients who had received \u22651 injection of aboBoNT-A in line with the Summary of Product Characteristics. Primary endpoints were the average aboBoNT-A dose received per treatment cycle and average interval between cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For the 108 patients included, the median (Q1, Q3) age was 52.5 (41.0, 69.0) years and the most common underlying neurological condition was stroke (61.1%). The mean (SD) total dose of aboBoNT-A received was 540.8 (268.5) U (cycle 1), 586.1 (279.4) U (cycle 2), 558.0 (258.5) U (cycle 3), and 464.3 (209.6) U (cycle 4). The mean (SD) interval between cycles was 153.8 (56.9) days. Of 82 goals assessed, 71 (86.6%) were achieved. Seven patients (5.8%) in the safety population (\n                      <jats:italic toggle=\"yes\">N\u2009<\/jats:italic>\n                      =\u2009121) experienced adverse events, none of which were considered related to aboBoNT-A treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data further document aboBoNT-A as an effective and well-tolerated treatment for adult focal spasticity, supporting use in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10538135251325755","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T18:14:43Z","timestamp":1742494483000},"page":"525-534","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A Multicenter, Retrospective, Real-World Study of Treatment Outcomes Following on-label AbobotulinumtoxinA Injections for Adult Focal Spasticity in the United Kingdom"],"prefix":"10.1177","volume":"56","author":[{"given":"Moheb","family":"Gaid","sequence":"first","affiliation":[{"name":"Colman Centre for Specialist Rehabilitation Services, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Brown","sequence":"additional","affiliation":[{"name":"York and Scarborough Teaching Hospitals NHS Foundation Trust, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Ippolito","sequence":"additional","affiliation":[{"name":"Ipsen, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Degtiar","sequence":"additional","affiliation":[{"name":"Ipsen, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3469-7261","authenticated-orcid":false,"given":"Pascal","family":"Maisonobe","sequence":"additional","affiliation":[{"name":"Ipsen, Boulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Orridge","sequence":"additional","affiliation":[{"name":"King's College Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.31.10.2402"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1133390"},{"key":"e_1_3_5_4_1","article-title":"European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and\/or botulinum toxin type A","volume":"54","author":"Biering-Soerensen B.","year":"2022","unstructured":"Biering-Soerensen B., Stevenson V., Bensmail D., Grabljevec K., Mart\u00ednez Moreno M., Pucks-Faes E., Wissel J., Zampolini M. (2022). European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and\/or botulinum toxin type A. Journal of Rehabilitation Medicine, 54, jrm00241. https:\/\/doi.org\/10.2340\/16501977-2877","journal-title":"Journal of Rehabilitation Medicine"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/67.2.206"},{"key":"e_1_3_5_6_1","unstructured":"ClinicalTrials.gov. (2021). A study to assess treatment outcomes of abobotulinumtoxinA and onabotulinumtoxinA treatments in real life practice in toxin-na\u00efve adult patients with limb spasticity. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04396704"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1957582"},{"key":"e_1_3_5_8_1","unstructured":"Electronic Medicines Compendium. (2023a). Dysport 300 units - Summary of Product Characteristics (SmPC). https:\/\/www.medicines.org.uk\/emc\/product\/964\/smpc"},{"key":"e_1_3_5_9_1","unstructured":"Electronic Medicines Compendium. (2023b). Dysport 500 units - Summary of Product Characteristics (SmPC). https:\/\/www.medicines.org.uk\/emc\/product\/7261\/smpc"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2024.10.017"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/09638280500404305"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e318296e630"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.11.022"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/11206340-000000000-00000"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.1689"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/09638280400014576"},{"key":"e_1_3_5_17_1","unstructured":"Royal College of Physicians. (2018). Spasticity in adults: management using botulinum toxin. https:\/\/www.rcplondon.ac.uk\/guidelines-policy\/spasticity-adults-management-using-botulinum-toxin"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.5603\/PJNNS.a2020.0004"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.2340\/16501977-0474"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.2340\/16501977-2801"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.2-2-128"},{"key":"e_1_3_5_22_1","unstructured":"U.S. Food and Drug Administration. (2020). Dysport - highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125274Orig1s118lbl.pdf"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1191\/0269215505cr827oa"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2002.0090s1048.x"},{"issue":"3","key":"e_1_3_5_25_1","article-title":"Toward an epidemiology of poststroke spasticity","volume":"80","author":"Wissel J.","year":"2013","unstructured":"Wissel J., Manack A., Brainin M. (2013). Toward an epidemiology of poststroke spasticity. Neurology, 80(3 Suppl 2), S13\u2013S19. https:\/\/doi.org\/10.1212\/WNL.0b013e3182762448","journal-title":"Neurology"}],"container-title":["NeuroRehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10538135251325755","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10538135251325755","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10538135251325755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:43:55Z","timestamp":1793364235000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10538135251325755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/10538135251325755"],"URL":"https:\/\/doi.org\/10.1177\/10538135251325755","relation":{},"ISSN":["1053-8135","1878-6448"],"issn-type":[{"value":"1053-8135","type":"print"},{"value":"1878-6448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}